Bioventus Inc. (BVS)
| Market Cap | 767.68M +77.2% |
| Revenue (ttm) | 576.30M +1.5% |
| Net Income | 28.48M |
| EPS | 0.40 |
| Shares Out | 83.53M |
| PE Ratio | 22.80 |
| Forward PE | 11.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 196,200 |
| Open | 9.18 |
| Previous Close | 9.20 |
| Day's Range | 9.11 - 9.39 |
| 52-Week Range | 5.81 - 11.25 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 14.80 (+61.05%) |
| Earnings Date | May 6, 2026 |
About BVS
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for BVS stock is "Strong Buy." The 12-month stock price target is $14.8, which is an increase of 61.05% from the latest price.
News
Bioventus Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Revenue and margin growth continue, with 2026 guidance at $605 million and EBITDA margins above 20%. Focus is on debt reduction, investing in high-growth products like PNS and PRP, and expanding internationally. Portfolio and profitability improvements are supported by disciplined capital allocation and strong execution.
Bioventus Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and governance procedures. All director nominees were elected and the auditor appointment was ratified, with final vote results to be published in a Form 8-K. No shareholder questions were submitted.
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President an...
Bioventus reports Q1 EPS 15c, consensus 7c
Reports Q1 revenue $132.09M, consensus $129.9M. “Our team delivered a strong start to 2026, driven by continued momentum in our core businesses and disciplined execution across our commercial and oper...
Bioventus raises FY26 adjusted EPS view to 75c-79c from 73c-77c
Consensus 75c. Backs FY26 revenue view $600M-$610M, consensus $604.86M. Raises FY26 cash from operations view to $84M-$89M from $82M-$87M. The company said, “Based on accelerated cash flow and faster ...
Bioventus Earnings Call Transcript: Q1 2026
Q1 2026 saw 7% revenue growth, 24% higher adjusted EBITDA, and record cash flow, driven by strong execution and investments in key growth drivers. Full-year guidance for adjusted EPS and cash from operations was raised, with accelerating growth expected in the second half.
Bioventus Earnings release: Q1 2026
Bioventus released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Bioventus Quarterly report: Q1 2026
Bioventus has published its Q1 2026 quarterly earnings report on May 6, 2026.
Bioventus Slides: Q1 2026
Bioventus has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Bioventus Reports First Quarter Financial Results
DURHAM, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the ...
Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026
DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fin...
Bioventus Proxy statement: Proxy filing
Bioventus filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Bioventus Proxy statement: Proxy filing
Bioventus filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Bioventus initiated with an Outperform at CJS Securities
CJS Securities analyst Lawrence Solow initiated coverage of Bioventus (BVS) with an Outperform rating and $14 price target
Bioventus Slides: Corporate presentation
Bioventus has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
Bioventus management to meet with Barrington
Meeting to be held in Denver on March 18 hosted by Barrington.
Bioventus price target raised to $16 from $15 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Bioventus (BVS) to $16 from $15 and keeps a Buy rating on the shares following the company’s strong quarter and solid guide. The…
Bioventus price target raised to $14 from $13 at Barrington
Barrington raised the firm’s price target on Bioventus (BVS) to $14 from $13 and keeps an Outperform rating on the shares. The firm cites the company’s “strong” Q4 report and…
Bioventus Earnings Call Transcript: Q4 2025
Delivered 10% organic revenue growth in Q4 2025, with record cash flow and margin expansion. 2026 guidance targets $600–$610 million in sales, EPS of $0.73–$0.77, and continued investment in growth drivers like PNS, PRP, and Ultrasonics.
Bioventus Annual report: Q4 2025
Bioventus has published its Q4 2025 annual report on March 5, 2026.
Bioventus Earnings release: Q4 2025
Bioventus released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Bioventus Slides: Q4 2025
Bioventus has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 5, 2026.
Bioventus sees FY26 adjusted EPS 73c-77c, consensus 77c
Sees FY26 revenue $600M-$610M, consensus $604.18M
Bioventus reports Q4 EPS 24c, consensus 22c
Reports Q4 revenue $157.9M, consensus $154.95M. “Our team delivered strong fourth quarter performance, concluding an important year in which we strengthened our portfolio, drove above-market growth, i...
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP ea...